Biotech Investors & VC Firms in Netherlands

75 firms in this list, with a median first check of $540K. 21 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
DR Droia Ventures GGJNLBLD13 people · Follows rounds	88🔒	Leuven	BE	Pre-Seed–Series B	$540K	+ Add to CRM
SO Sonder Capital JWKGDKFM15 people	88🔒	San Carlos	US	Pre-Seed–Late Stage	—	+ Add to CRM
TE TechVision Fund BKBLDAPB17 people · Leads rounds	88🔒	Aachen	DE	Pre-Seed–Series A	$550K – $2.2M	+ Add to CRM
NE Newton Biocapital APGTAWPD16 people · Leads rounds	88🔒	Brussels	BE	Seed–Series A	—	+ Add to CRM
CL Clay Capital MDMVAMGC16 people	88🔒	—	SG	Seed–Late Stage	$3M – $8M	+ Add to CRM
PA PAI Partners AAKBAAWP13 people	88🔒	Paris	FR	Growth–Late Stage	$108M – $324M	+ Add to CRM
SU Supermoon Capital PCGJMMCZ7 people · Leads rounds	88🔒	San Francisco	US	Pre-Seed–Series A	$150K – $2.5M	+ Add to CRM
GI Gimv AJLTMMPV11 people · Leads rounds	88🔒	Antwerp	BE	Growth–Late Stage	$21M – $430M	+ Add to CRM
AB AbbVie CLSGACCV13 people · Follows rounds	88🔒	Cambridge	US	Seed–Late Stage	$300K – $3M	+ Add to CRM
PU Pureos Bioventures DEKBMMVG9 people	88🔒	Pfäffikon	CH	Seed–Series C	—	+ Add to CRM
RT RTW Investments L.P. GMJMJKLC14 people	88🔒	New York	US	Seed–Series A	—	+ Add to CRM
NO Novalis Biotech JVWVBRCB7 people	88🔒	Ghent	BE	Pre-Seed–Series A	—	+ Add to CRM
DB DBH Investment Zrt. DFDJLÜMJ9 people	88🔒	Budapest	HU	Seed–Series B	$216K – $1.6M	+ Add to CRM
VE Vesalius Biocapital III Partners SàRL CSGGMLSV12 people	88🔒	Contern	LU	Seed–Late Stage	$10.8M	+ Add to CRM
TV TVM Capital DHHBSFDH6 people · Leads rounds	88🔒	Munich	DE	Seed–Late Stage	$1.1M – $16.2M	+ Add to CRM
FU Future Positive Capital PR1 person · Follows rounds	88🔒	—	FR	Pre-Seed–Series A	—	+ Add to CRM
ED EDB Investments CKCLCGJO11 people	88🔒	Singapore	SG	Seed–Late Stage	$12M – $400M	+ Add to CRM
VE Vento DDJKTMIT4 people · Follows rounds	88🔒	Torino	IT	Pre-Seed–Seed	$165K – $1.1M	+ Add to CRM
BR Bridford Investments (Bridford Group) TH1 person · Leads rounds	88🔒	London	GB	Pre-Seed–Growth	—	+ Add to CRM
HE HEARTFELT_ Follows rounds	88🔒	Berlin	DE	Pre-Seed–Series A	$110K – $440K	+ Add to CRM
AL Alpina Partners NPFS2 people · Leads rounds	88🔒	Munich	DE	Series A–Late Stage	$635K – $2.5M	+ Add to CRM
CA Cancer Focus RPAGDRMM4 people	88🔒	Houston	US	Pre-Seed–Series A	—	+ Add to CRM
AD Adinvest AG NVCSDUHS4 people	88🔒	Zug	CH	—	—	+ Add to CRM
ME MedCap AB LÅKEAD3 people	88🔒	Stockholm	SE	Seed–Series A	—	+ Add to CRM

Droia Ventures

LeuvenPre-Seed–Series B$540K

GGJNLBLD13 people

Sonder Capital

San CarlosPre-Seed–Late Stage

JWKGDKFM15 people

TechVision Fund

AachenPre-Seed–Series A$550K – $2.2M

BKBLDAPB17 people

Newton Biocapital

BrusselsSeed–Series A

APGTAWPD16 people

Clay Capital

Seed–Late Stage$3M – $8M

MDMVAMGC16 people

PAI Partners

ParisGrowth–Late Stage$108M – $324M

AAKBAAWP13 people

Supermoon Capital

San FranciscoPre-Seed–Series A$150K – $2.5M

PCGJMMCZ7 people

Gimv

AntwerpGrowth–Late Stage$21M – $430M

AJLTMMPV11 people

AbbVie

CambridgeSeed–Late Stage$300K – $3M

CLSGACCV13 people

Pureos Bioventures

PfäffikonSeed–Series C

DEKBMMVG9 people

RTW Investments L.P.

New YorkSeed–Series A

GMJMJKLC14 people

Novalis Biotech

GhentPre-Seed–Series A

JVWVBRCB7 people

DBH Investment Zrt.

BudapestSeed–Series B$216K – $1.6M

DFDJLÜMJ9 people

Vesalius Biocapital III Partners SàRL

ConternSeed–Late Stage$10.8M

CSGGMLSV12 people

TVM Capital

MunichSeed–Late Stage$1.1M – $16.2M

DHHBSFDH6 people

Future Positive Capital

Pre-Seed–Series A

PR1 person

EDB Investments

SingaporeSeed–Late Stage$12M – $400M

CKCLCGJO11 people

Vento

TorinoPre-Seed–Seed$165K – $1.1M

DDJKTMIT4 people

Bridford Investments (Bridford Group)

LondonPre-Seed–Growth

TH1 person

HEARTFELT_

BerlinPre-Seed–Series A$110K – $440K

Alpina Partners

MunichSeries A–Late Stage$635K – $2.5M

NPFS2 people

Cancer Focus

HoustonPre-Seed–Series A

RPAGDRMM4 people

Adinvest AG

Zug

NVCSDUHS4 people

MedCap AB

StockholmSeed–Series A

LÅKEAD3 people

Data sourced from public filings and firms' own websites — see our methodology.